search
Back to results

Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure (STOP)

Primary Purpose

Patent Foramen Ovale, Cryptogenic Stroke, Older Patients

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Transcatheter PFO closure
Optimal medical treatment
Sponsored by
Josep Rodes-Cabau
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Patent Foramen Ovale

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Cryptogenic stroke Age >60 years Right-to-left shunt as evaluated by echocardiography (TEE). Exclusion Criteria: -≤60 year-old Lacunar (small vessel) stroke. Permanent or paroxysmal atrial fibrillation/flutter (clinically apparent or detected by continuous ECG monitoring). Need for chronic anticoagulation therapy. Any contraindication for antiplatelet therapy (aspirin, clopidogrel, ticagrelor). Presence of extracranial or intracranial atherosclerosis causing ≥50% luminal --stenosis in arteries supplying the area of ischemia. Presence of complex atheroma plaques at the ascending aorta-aortic arch (≥4-mm-thick, ulcerated or containing mobile thrombi) as evaluated by TEE. Presence of intracardiac thrombus as evaluated by TEE. Uncontrolled hypertension (systemic pressure values >160/90 mmHg despite optimal medical treatment). History of myocardial infarction or coronary intervention. (percutaneous coronary intervention, coronary artery bypass graft). History of prior valve surgery or transcatheter valve repair. Presence of deep venous thrombosis at the time of index stroke as evaluated by Doppler ultrasonography. Left ventricular ejection fraction <50% as evaluated by TTE. Significant (moderate or severe) valvular disease as evaluated by echocardiography. History of congestive heart failure. Severe chronic kidney dysfunction defined an estimated glomerular filtration rate <30 ml/min/m2 or need for dialysis. Isolated ASD or ASD associated with PFO but with a hemodynamically significant left-to-right shunt requiring closure. Other specific cause of stroke identified (eg, arteritis, dissection, migraine/vasospasm, and drug abuse). Prior surgical or endovascular treatments of PFO or ASD. Rheumatic heart disease. Left atrial enlargement defined as a left atrial diameter >41 mm in men and ≥39 mm in women. Presence of high burden of premature atrial contractions (>500 per 24 hrs) as evaluated by continuous ECG monitoring. Follow-up impossible or expected poor compliance. Active cancer. Presence of an inferior vena cava filter. Severe pulmonary artery hypertension (systolic pulmonary pressure >60 mmHg). Functional dependency as measured by a modified Rankin Scale score >3 (unable to attend to own bodily needs without assistance and unable to walk unassisted). Any medical condition determining a life expectancy <2 years. Participation in another randomized study. Failure to provide signed informed consent.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Experimental

    Arm Label

    transcatheter PFO closure + optimal medical treatment

    Optimal medical treatment

    Arm Description

    Patients will undergoes transcatheter PFO closure (+ optimal medical treatment). Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.

    Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.

    Outcomes

    Primary Outcome Measures

    Rate of ischemic events
    New ischemic non-lacunar stroke events

    Secondary Outcome Measures

    Rate of stroke events
    All new non-lacunar stroke events
    Rate of mortality
    All cause mortality
    Rate of cardiovascular mortality
    Cardiovascular death
    Incidence of cerebral hemorrhage
    Cerebral bleeding
    Rate of new-onset atrial fibrillation
    All new onset atrial fibrillation episodes
    Rate of bleeding
    Major/life-threatening bleeding
    Health-related quality of life
    Evaluated by the EQ-5D-5L questionnaire
    Neurocognitive assessment
    Evaluated by the MoCA questionnaire

    Full Information

    First Posted
    June 8, 2023
    Last Updated
    September 6, 2023
    Sponsor
    Josep Rodes-Cabau
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05907694
    Brief Title
    Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure
    Acronym
    STOP
    Official Title
    Medical Treatment With or Without Transcatheter Patent Foramen Ovale CloSure for Older Patients With CrypTogenic StrOke and Patent Foramen Ovale. The STOP Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    October 1, 2023 (Anticipated)
    Primary Completion Date
    October 1, 2026 (Anticipated)
    Study Completion Date
    October 1, 2036 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Josep Rodes-Cabau

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Patent foramen ovale PFO closure has been shown to reduce the risk of stroke in patients with recurrent stroke. However, the majority of existing clinical studies in this field excluded patients over the age of 60 years. Data in older patients is limited and since the population ages and stroke remains a major cause of death and morbidity, randomized clinical trials are needed to better assess the benefit of PFO closure in this elderly population. Therefore, this study proposal sought to determine the efficacy of PFO closure for the prevention of recurrent stroke in older patients with PFO and cryptogenic stroke.
    Detailed Description
    Background and importance Consistent with studies performed in younger patient cohorts, older patients suffering a cryptogenic stroke exhibit a much higher prevalence of patent foramen ovale (PFO) compared to their stroke of known origin counterparts. Several studies have provided promising preliminary data regarding PFO closure in older patients with cryptogenic stroke, with very low stroke recurrence rates at mid- to long-term follow-up. Several randomized trials have shown the beneficial effects of PFO closure vs. medical treatment in patients younger than 60 years with cryptogenic stroke and PFO. Current observational data suggest similar or even more marked effects on stroke recurrence prevention of PFO closure in older patients and would support the design of a randomized trial to provide definite evidence in this field. Therefore, the objective of the present study is to evaluate the efficacy of transcatheter PFO closure for preventing recurrent ischemic stroke (nonlacunar) events in patients >60 years diagnosed with a cryptogenic stroke and PFO.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Patent Foramen Ovale, Cryptogenic Stroke, Older Patients, Medical Treatment, Recurrent Stroke

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    Randomized controlled trial comparing transcatheter PFO closure + medical treatment vs. medical treatment alone.
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    714 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    transcatheter PFO closure + optimal medical treatment
    Arm Type
    Experimental
    Arm Description
    Patients will undergoes transcatheter PFO closure (+ optimal medical treatment). Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
    Arm Title
    Optimal medical treatment
    Arm Type
    Experimental
    Arm Description
    Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
    Intervention Type
    Procedure
    Intervention Name(s)
    Transcatheter PFO closure
    Intervention Description
    Transcatheter PFO closure procedure will be performed according to the standards and experience of each participating center. Any approved PFO occluder device will be allowed in the study. Patients will also receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
    Intervention Type
    Drug
    Intervention Name(s)
    Optimal medical treatment
    Intervention Description
    Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
    Primary Outcome Measure Information:
    Title
    Rate of ischemic events
    Description
    New ischemic non-lacunar stroke events
    Time Frame
    12 months
    Secondary Outcome Measure Information:
    Title
    Rate of stroke events
    Description
    All new non-lacunar stroke events
    Time Frame
    12 months
    Title
    Rate of mortality
    Description
    All cause mortality
    Time Frame
    10 year follow-up
    Title
    Rate of cardiovascular mortality
    Description
    Cardiovascular death
    Time Frame
    10 year follow-up
    Title
    Incidence of cerebral hemorrhage
    Description
    Cerebral bleeding
    Time Frame
    10 year follow-up
    Title
    Rate of new-onset atrial fibrillation
    Description
    All new onset atrial fibrillation episodes
    Time Frame
    10 year follow-up
    Title
    Rate of bleeding
    Description
    Major/life-threatening bleeding
    Time Frame
    10 year follow-up
    Title
    Health-related quality of life
    Description
    Evaluated by the EQ-5D-5L questionnaire
    Time Frame
    10 year follow-up
    Title
    Neurocognitive assessment
    Description
    Evaluated by the MoCA questionnaire
    Time Frame
    10 year follow-up

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Cryptogenic stroke Age >60 years Right-to-left shunt as evaluated by echocardiography (TEE). Exclusion Criteria: -≤60 year-old Lacunar (small vessel) stroke. Permanent or paroxysmal atrial fibrillation/flutter (clinically apparent or detected by continuous ECG monitoring). Need for chronic anticoagulation therapy. Any contraindication for antiplatelet therapy (aspirin, clopidogrel, ticagrelor). Presence of extracranial or intracranial atherosclerosis causing ≥50% luminal --stenosis in arteries supplying the area of ischemia. Presence of complex atheroma plaques at the ascending aorta-aortic arch (≥4-mm-thick, ulcerated or containing mobile thrombi) as evaluated by TEE. Presence of intracardiac thrombus as evaluated by TEE. Uncontrolled hypertension (systemic pressure values >160/90 mmHg despite optimal medical treatment). History of myocardial infarction or coronary intervention. (percutaneous coronary intervention, coronary artery bypass graft). History of prior valve surgery or transcatheter valve repair. Presence of deep venous thrombosis at the time of index stroke as evaluated by Doppler ultrasonography. Left ventricular ejection fraction <50% as evaluated by TTE. Significant (moderate or severe) valvular disease as evaluated by echocardiography. History of congestive heart failure. Severe chronic kidney dysfunction defined an estimated glomerular filtration rate <30 ml/min/m2 or need for dialysis. Isolated ASD or ASD associated with PFO but with a hemodynamically significant left-to-right shunt requiring closure. Other specific cause of stroke identified (eg, arteritis, dissection, migraine/vasospasm, and drug abuse). Prior surgical or endovascular treatments of PFO or ASD. Rheumatic heart disease. Left atrial enlargement defined as a left atrial diameter >41 mm in men and ≥39 mm in women. Presence of high burden of premature atrial contractions (>500 per 24 hrs) as evaluated by continuous ECG monitoring. Follow-up impossible or expected poor compliance. Active cancer. Presence of an inferior vena cava filter. Severe pulmonary artery hypertension (systolic pulmonary pressure >60 mmHg). Functional dependency as measured by a modified Rankin Scale score >3 (unable to attend to own bodily needs without assistance and unable to walk unassisted). Any medical condition determining a life expectancy <2 years. Participation in another randomized study. Failure to provide signed informed consent.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Josep Rodes-Cabau, MD, PhD
    Phone
    4186568711
    Email
    josep.rodes@criucpq.ulaval.ca
    First Name & Middle Initial & Last Name or Official Title & Degree
    Melanie Cote, MSc
    Phone
    4186568711
    Ext
    2646
    Email
    melanie.cote@criucpq.ulaval.ca
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    IUCPQ Rodes-Cabau, MD, PhD
    Organizational Affiliation
    Fondation IUCPQ
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    34024117
    Citation
    Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, Lennon O, Meschia JF, Nguyen TN, Pollak PM, Santangeli P, Sharrief AZ, Smith SC Jr, Turan TN, Williams LS. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467. doi: 10.1161/STR.0000000000000375. Epub 2021 May 24. No abstract available. Erratum In: Stroke. 2021 Jul;52(7):e483-e484.
    Results Reference
    background
    PubMed Identifier
    30879893
    Citation
    GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):459-480. doi: 10.1016/S1474-4422(18)30499-X. Epub 2019 Mar 14.
    Results Reference
    background
    PubMed Identifier
    35078371
    Citation
    Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme AK, Buxton AE, Carson AP, Commodore-Mensah Y, Elkind MSV, Evenson KR, Eze-Nliam C, Ferguson JF, Generoso G, Ho JE, Kalani R, Khan SS, Kissela BM, Knutson KL, Levine DA, Lewis TT, Liu J, Loop MS, Ma J, Mussolino ME, Navaneethan SD, Perak AM, Poudel R, Rezk-Hanna M, Roth GA, Schroeder EB, Shah SH, Thacker EL, VanWagner LB, Virani SS, Voecks JH, Wang NY, Yaffe K, Martin SS. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022 Feb 22;145(8):e153-e639. doi: 10.1161/CIR.0000000000001052. Epub 2022 Jan 26. Erratum In: Circulation. 2022 Sep 6;146(10):e141.
    Results Reference
    background
    PubMed Identifier
    30888967
    Citation
    Zhao W, Wu J, Liu J, Wu Y, Ni J, Gu H, Tu J, Wang J, An Z, Ning X. Trends in the incidence of recurrent stroke at 5 years after the first-ever stroke in rural China: a population-based stroke surveillance from 1992 to 2017. Aging (Albany NY). 2019 Mar 19;11(6):1686-1694. doi: 10.18632/aging.101862.
    Results Reference
    background
    PubMed Identifier
    34218432
    Citation
    Cho KK, Khanna S, Lo P, Cheng D, Roy D. Persistent pathology of the patent foramen ovale: a review of the literature. Med J Aust. 2021 Jul;215(2):89-93. doi: 10.5694/mja2.51141. Epub 2021 Jul 4.
    Results Reference
    background
    PubMed Identifier
    35225286
    Citation
    Molnar AA, Abraham P, Merkely B, Nardai S. Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure. J Vis Exp. 2022 Feb 8;(180). doi: 10.3791/61240.
    Results Reference
    background
    PubMed Identifier
    12664815
    Citation
    Ho SY, McCarthy KP, Rigby ML. Morphological features pertinent to interventional closure of patent oval foramen. J Interv Cardiol. 2003 Feb;16(1):33-8. doi: 10.1046/j.1540-8183.2003.08000.x.
    Results Reference
    background
    PubMed Identifier
    22814784
    Citation
    Agarwal S, Bajaj NS, Kumbhani DJ, Tuzcu EM, Kapadia SR. Meta-analysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism. JACC Cardiovasc Interv. 2012 Jul;5(7):777-89. doi: 10.1016/j.jcin.2012.02.021.
    Results Reference
    background
    PubMed Identifier
    19443800
    Citation
    Alsheikh-Ali AA, Thaler DE, Kent DM. Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke. 2009 Jul;40(7):2349-55. doi: 10.1161/STROKEAHA.109.547828. Epub 2009 May 14.
    Results Reference
    background
    PubMed Identifier
    3362165
    Citation
    Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M, Drobinski G, Thomas D, Grosgogeat Y. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med. 1988 May 5;318(18):1148-52. doi: 10.1056/NEJM198805053181802.
    Results Reference
    background
    PubMed Identifier
    18046029
    Citation
    Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 2007 Nov 29;357(22):2262-8. doi: 10.1056/NEJMoa071422.
    Results Reference
    background
    PubMed Identifier
    30358849
    Citation
    Pristipino C, Sievert H, D'Ascenzo F, Louis Mas J, Meier B, Scacciatella P, Hildick-Smith D, Gaita F, Toni D, Kyrle P, Thomson J, Derumeaux G, Onorato E, Sibbing D, Germonpre P, Berti S, Chessa M, Bedogni F, Dudek D, Hornung M, Zamorano J; Evidence Synthesis Team; Eapci Scientific Documents and Initiatives Committee; International Experts. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. Eur Heart J. 2019 Oct 7;40(38):3182-3195. doi: 10.1093/eurheartj/ehy649. Erratum In: Eur Heart J. 2021 May 7;42(18):1807.
    Results Reference
    background
    PubMed Identifier
    33611943
    Citation
    Chen JZ, Thijs VN. Atrial Fibrillation Following Patent Foramen Ovale Closure: Systematic Review and Meta-Analysis of Observational Studies and Clinical Trials. Stroke. 2021 May;52(5):1653-1661. doi: 10.1161/STROKEAHA.120.030293. Epub 2021 Feb 22.
    Results Reference
    background
    PubMed Identifier
    29332308
    Citation
    Hakeem A, Cilingiroglu M, Katramados A, Boudoulas KD, Iliescu C, Gundogdu B, Marmagkiolis K. Transcatheter closure of patent foramen ovale for secondary prevention of ischemic stroke: Quantitative synthesis of pooled randomized trial data. Catheter Cardiovasc Interv. 2018 Nov 15;92(6):1153-1160. doi: 10.1002/ccd.27487. Epub 2018 Jan 14.
    Results Reference
    background
    PubMed Identifier
    34653958
    Citation
    Musto C, Cifarelli A, Dipasquale F, Chin D, Nazzaro MS, Stio RE, Pennacchi M, De Felice F. A Comparison Between Gore Cardioform and Amplatzer Septal Occluder for Percutaneous Closure of Patent Foramen Ovale Associated With Atrial Septal Aneurysm: Clinical and Echocardiographic Outcomes. J Invasive Cardiol. 2021 Nov;33(11):E857-E862. Epub 2021 Oct 15.
    Results Reference
    background
    PubMed Identifier
    28902580
    Citation
    Sondergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, Settergren M, Sjostrand C, Roine RO, Hildick-Smith D, Spence JD, Thomassen L; Gore REDUCE Clinical Study Investigators. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. N Engl J Med. 2017 Sep 14;377(11):1033-1042. doi: 10.1056/NEJMoa1707404. Erratum In: N Engl J Med. 2020 Mar 5;382(10):978.
    Results Reference
    background
    PubMed Identifier
    29544871
    Citation
    Lee PH, Song JK, Kim JS, Heo R, Lee S, Kim DH, Song JM, Kang DH, Kwon SU, Kang DW, Lee D, Kwon HS, Yun SC, Sun BJ, Park JH, Lee JH, Jeong HS, Song HJ, Kim J, Park SJ. Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial. J Am Coll Cardiol. 2018 May 22;71(20):2335-2342. doi: 10.1016/j.jacc.2018.02.046. Epub 2018 Mar 12.
    Results Reference
    background
    PubMed Identifier
    28902593
    Citation
    Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, Arquizan C, Bejot Y, Vuillier F, Detante O, Guidoux C, Canaple S, Vaduva C, Dequatre-Ponchelle N, Sibon I, Garnier P, Ferrier A, Timsit S, Robinet-Borgomano E, Sablot D, Lacour JC, Zuber M, Favrole P, Pinel JF, Apoil M, Reiner P, Lefebvre C, Guerin P, Piot C, Rossi R, Dubois-Rande JL, Eicher JC, Meneveau N, Lusson JR, Bertrand B, Schleich JM, Godart F, Thambo JB, Leborgne L, Michel P, Pierard L, Turc G, Barthelet M, Charles-Nelson A, Weimar C, Moulin T, Juliard JM, Chatellier G; CLOSE Investigators. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med. 2017 Sep 14;377(11):1011-1021. doi: 10.1056/NEJMoa1705915.
    Results Reference
    background
    PubMed Identifier
    28902590
    Citation
    Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med. 2017 Sep 14;377(11):1022-1032. doi: 10.1056/NEJMoa1610057.
    Results Reference
    background
    PubMed Identifier
    29602754
    Citation
    Wang TKM, Wang MTM, Ruygrok P. Patent Foramen Ovale Closure Versus Medical Therapy for Cryptogenic Stroke: Meta-Analysis of Randomised Trials. Heart Lung Circ. 2019 Apr;28(4):623-631. doi: 10.1016/j.hlc.2018.02.023. Epub 2018 Mar 12.
    Results Reference
    background
    PubMed Identifier
    34455822
    Citation
    Messe SR, Erus G, Bilello M, Davatzikos C, Andersen G, Iversen HK, Roine RO, Sjostrand C, Rhodes JF, Sondergaard L, Kasner SE; Gore REDUCE Study Investigators. Patent Foramen Ovale Closure Decreases the Incidence but Not the Size of New Brain Infarction on Magnetic Resonance Imaging: An Analysis of the REDUCE Trial. Stroke. 2021 Nov;52(11):3419-3426. doi: 10.1161/STROKEAHA.121.034451. Epub 2021 Aug 30.
    Results Reference
    background
    PubMed Identifier
    34140063
    Citation
    Gladstone DJ, Lindsay MP, Douketis J, Smith EE, Dowlatshahi D, Wein T, Bourgoin A, Cox J, Falconer JB, Graham BR, Labrie M, McDonald L, Mandzia J, Ngui D, Pageau P, Rodgerson A, Semchuk W, Tebbutt T, Tuchak C, van Gaal S, Villaluna K, Foley N, Coutts S, Mountain A, Gubitz G, Udell JA, McGuff R, Heran MKS, Lavoie P, Poppe AY; Canadian Stroke Consortium. Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Update 2020. Can J Neurol Sci. 2022 May;49(3):315-337. doi: 10.1017/cjn.2021.127. Epub 2021 Jun 18. Erratum In: Can J Neurol Sci. 2023 May;50(3):481. Heran, Manraj KS; Lavoie, Pascale [added].
    Results Reference
    background
    PubMed Identifier
    19463412
    Citation
    Wahl A, Tai T, Praz F, Schwerzmann M, Seiler C, Nedeltchev K, Windecker S, Mattle HP, Meier B. Late results after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism using the amplatzer PFO occluder without intraprocedural echocardiography: effect of device size. JACC Cardiovasc Interv. 2009 Feb;2(2):116-23. doi: 10.1016/j.jcin.2008.09.013.
    Results Reference
    background
    PubMed Identifier
    31585849
    Citation
    Wintzer-Wehekind J, Alperi A, Houde C, Cote JM, Del Val D, Cote M, Rodes-Cabau J. Transcatheter closure of patent foramen ovale in patients older than 60 years of age with cryptogenic embolism. Rev Esp Cardiol (Engl Ed). 2020 Mar;73(3):219-224. doi: 10.1016/j.rec.2019.07.003. Epub 2019 Oct 1. English, Spanish.
    Results Reference
    background
    PubMed Identifier
    35735021
    Citation
    Alperi A, Guedeney P, Horlick E, Nombela-Franco L, Freixa X, Pascual I, Mesnier J, Houde C, Abrahamyan L, Montalescot G, Rodes-Cabau J. Transcatheter Closure of Patent Foramen Ovale in Older Patients With Cryptogenic Thromboembolic Events. Circ Cardiovasc Interv. 2022 Jul;15(7):e011652. doi: 10.1161/CIRCINTERVENTIONS.121.011652. Epub 2022 Jun 23.
    Results Reference
    background
    PubMed Identifier
    32628255
    Citation
    Mazzucco S, Li L, Rothwell PM. Prognosis of Cryptogenic Stroke With Patent Foramen Ovale at Older Ages and Implications for Trials: A Population-Based Study and Systematic Review. JAMA Neurol. 2020 Oct 1;77(10):1279-1287. doi: 10.1001/jamaneurol.2020.1948.
    Results Reference
    background
    PubMed Identifier
    15232117
    Citation
    Homma S, DiTullio MR, Sacco RL, Sciacca RR, Mohr JP; PICSS Investigators. Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. Stroke. 2004 Sep;35(9):2145-9. doi: 10.1161/01.STR.0000135773.24116.18. Epub 2004 Jul 1.
    Results Reference
    background
    PubMed Identifier
    16755591
    Citation
    Kiblawi FM, Sommer RJ, Levchuck SG. Transcatheter closure of patent foramen ovale in older adults. Catheter Cardiovasc Interv. 2006 Jul;68(1):136-42; discussion 143-4. doi: 10.1002/ccd.20722.
    Results Reference
    background
    PubMed Identifier
    18942060
    Citation
    Spies C, Khandelwal A, Timmemanns I, Kavinsky CJ, Schrader R, Hijazi ZM. Recurrent events following patent foramen ovale closure in patients above 55 years of age with presumed paradoxical embolism. Catheter Cardiovasc Interv. 2008 Dec 1;72(7):966-70. doi: 10.1002/ccd.21737.
    Results Reference
    background
    PubMed Identifier
    26106024
    Citation
    Scacciatella P, Meynet I, Presbitero P, Giorgi M, Lucarelli C, Zavalloni Parenti D, Biava LM, Marra S. Recurrent cerebral ischemia after patent foramen ovale percutaneous closure in older patients: A two-center registry study. Catheter Cardiovasc Interv. 2016 Feb 15;87(3):508-14. doi: 10.1002/ccd.26053. Epub 2015 Jun 23.
    Results Reference
    background
    PubMed Identifier
    32921262
    Citation
    Kent DM, Saver JL, Ruthazer R, Furlan AJ, Reisman M, Carroll JD, Smalling RW, Juni P, Mattle HP, Meier B, Thaler DE. Risk of Paradoxical Embolism (RoPE)-Estimated Attributable Fraction Correlates With the Benefit of Patent Foramen Ovale Closure: An Analysis of 3 Trials. Stroke. 2020 Oct;51(10):3119-3123. doi: 10.1161/STROKEAHA.120.029350. Epub 2020 Sep 14.
    Results Reference
    background
    PubMed Identifier
    24928123
    Citation
    Thaler DE, Ruthazer R, Weimar C, Mas JL, Serena J, Di Angelantonio E, Papetti F, Homma S, Mattle HP, Nedeltchev K, Mono ML, Jaigobin C, Michel P, Elkind MS, Di Tullio MR, Lutz JS, Griffith J, Kent DM. Recurrent stroke predictors differ in medically treated patients with pathogenic vs. other PFOs. Neurology. 2014 Jul 15;83(3):221-6. doi: 10.1212/WNL.0000000000000589. Epub 2014 Jun 13.
    Results Reference
    background
    PubMed Identifier
    23864310
    Citation
    Kent DM, Ruthazer R, Weimar C, Mas JL, Serena J, Homma S, Di Angelantonio E, Di Tullio MR, Lutz JS, Elkind MS, Griffith J, Jaigobin C, Mattle HP, Michel P, Mono ML, Nedeltchev K, Papetti F, Thaler DE. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology. 2013 Aug 13;81(7):619-25. doi: 10.1212/WNL.0b013e3182a08d59. Epub 2013 Jul 17.
    Results Reference
    background
    PubMed Identifier
    27027873
    Citation
    Taggart NW, Reeder GS, Lennon RJ, Slusser JP, Freund MA, Cabalka AK, Cetta F, Hagler DJ. Long-term follow-up after PFO device closure: Outcomes and Complications in a Single-center Experience. Catheter Cardiovasc Interv. 2017 Jan;89(1):124-133. doi: 10.1002/ccd.26518. Epub 2016 Mar 29.
    Results Reference
    background
    PubMed Identifier
    30678757
    Citation
    Wintzer-Wehekind J, Alperi A, Houde C, Cote JM, Asmarats L, Cote M, Rodes-Cabau J. Long-Term Follow-Up After Closure of Patent Foramen Ovale in Patients With Cryptogenic Embolism. J Am Coll Cardiol. 2019 Jan 29;73(3):278-287. doi: 10.1016/j.jacc.2018.10.061.
    Results Reference
    background
    PubMed Identifier
    29372390
    Citation
    Nezu T, Kitano T, Kubo S, Uemura J, Yamashita S, Iwanaga T, Inoue T, Hosomi N, Maruyama H, Matsumoto M, Kimura K, Yagita Y. Impact of D-dimer levels for short-term or long-term outcomes in cryptogenic stroke patients. J Neurol. 2018 Mar;265(3):628-636. doi: 10.1007/s00415-018-8742-x. Epub 2018 Jan 25.
    Results Reference
    background
    PubMed Identifier
    19628936
    Citation
    Weimar C, Holle DN, Benemann J, Schmid E, Schminke U, Haberl RL, Diener HC, Goertler M; German Stroke Study Collaboration. Current management and risk of recurrent stroke in cerebrovascular patients with right-to-left cardiac shunt. Cerebrovasc Dis. 2009;28(4):349-56. doi: 10.1159/000229553. Epub 2009 Jul 24.
    Results Reference
    background

    Learn more about this trial

    Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure

    We'll reach out to this number within 24 hrs